PMID- 10751572
OWN - NLM
STAT- MEDLINE
DCOM- 20000606
LR  - 20190614
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 861
IP  - 1
DP  - 2000 Apr 7
TI  - Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat 
      striatum after different kinds of pharmacological treatment.
PG  - 126-34
AB  - We recently identified the direct product of dopamine (DA) by monoamine-oxidase 
      (MAO) activity, dihydroxyphenylacetaldehyde (DOPALD) in the trans-striatal 
      dialysate. Based on these findings, in this work, we directly measured the 
      variations in DOPALD levels after various kinds of pharmacological treatment in 
      rat striatal extracellular fluid. Using both reversible and irreversible MAO 
      inhibitors, we found that MAO-A inhibition suppressed, whereas MAO-B inhibition 
      did not modify DOPALD levels in the dialysate. The vesicular DA uptake blocker Ro 
      4-1284 led to an increase in extracellular DA and DOPALD, whereas the increase in 
      extracellular DA obtained after administration of the plasma membrane DA uptake 
      blocker GBR-12909 occurred without concomitant changes in DOPALD extracellular 
      levels. Microinfusions of DA through the dialysis probe or systemic 
      administration of L-DOPA increased striatal DOPALD to a greater extent compared 
      with other DA metabolites, both in intact and in 6-hydroxydopamine 
      (6-OHDA)-lesioned striatum. This study indicates that the direct product of MAO 
      activity within the rat striatum derives from the activity of the isoenzyme 
      MAO-A. The assay of DOPALD, together with DOPAC, represents a reliable tool to 
      measure directly, in freely moving animals, DA oxidative metabolism. As recent 
      studies have shown that microinfusions of exogenous DOPALD might induce cell 
      death, pharmacological modulation of DOPALD levels might also be relevant for an 
      understanding of the mechanisms involved in DA neurotoxicity.
FAU - Fornai, F
AU  - Fornai F
AD  - Department of Human Morphology and Applied Biology, University of Pisa, Italy. 
      ffornai@drugs.med.unipi.it
FAU - Giorgi, F S
AU  - Giorgi FS
FAU - Bassi, L
AU  - Bassi L
FAU - Ferrucci, M
AU  - Ferrucci M
FAU - Alessandri, M G
AU  - Alessandri MG
FAU - Corsini, G U
AU  - Corsini GU
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Dopamine Agents)
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 46627O600J (Levodopa)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/*metabolism
MH  - Animals
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dopamine/*metabolism/pharmacology
MH  - Dopamine Agents/pharmacology
MH  - Dopamine Uptake Inhibitors/*pharmacology
MH  - Homovanillic Acid/*metabolism
MH  - Levodopa/pharmacology
MH  - Male
MH  - Monoamine Oxidase Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2000/04/07 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/04/07 09:00
PHST- 2000/04/07 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/04/07 09:00 [entrez]
AID - S0006-8993(00)02054-0 [pii]
AID - 10.1016/s0006-8993(00)02054-0 [doi]
PST - ppublish
SO  - Brain Res. 2000 Apr 7;861(1):126-34. doi: 10.1016/s0006-8993(00)02054-0.